Ra Pharmaceuticals racks up $58.5 mln Series B
Cambridge, Massachusetts-based biotech company Ra Pharmaceuticals has closed $58.5 million in Series B funding. RA Capital Management, Novo Ventures and Lightstone Ventures led the round with participation from other investors that included Rock Springs Capital Limulus Venture Partners, New Enterprise Associates, Novartis Venture Fund, Morgenthaler Ventures and Amgen Ventures. In conjunction with the funding, Rajeev Shah of RA Capital and Peter Tuxen Bisgaard of Novo Ventures (US) Inc have been added to Ra Pharma’s board of directors.
23 July 2015•3 mins read
